Business Context and Reporting Period
Company: Sharps Technology, Inc. (STSS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Historically a medical device manufacturer, the Company underwent a strategic pivot in August 2025. It adopted a digital asset treasury strategy focused on accumulating Solana (SOL) and ceased manufacturing operations to function primarily as a distributor. The Company now operates two segments: Medical Device Packaging and Digital Asset Treasury.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Total Revenue | $2.29 Million | $2.51 Million | $0 |
| (Product Revenue) | $83,622 | $306,344 | $0 |
| (Staking Revenue) | $2.21 Million | $2.21 Million | $0 |
| Net Loss | $(105.33) Million | $(99.85) Million | $(4.77) Million |
| Net Loss Per Share (Basic/Diluted) | $(4.33) | $(11.79) | $(1,358.58) |
| Cash and Cash Equivalents | $10.52 Million | $10.52 Million | $2.47 Million (End of Period) |
| Digital Assets (SOL & USDC) | $418.90 Million | $418.90 Million | $0 |
| Total Assets | $443.96 Million | $443.96 Million | $7.31 Million |
| Total Liabilities | $10.75 Million | $10.75 Million | $5.32 Million |
| Working Capital | $29.05 Million | $29.05 Million | $(2.01) Million Deficiency |
Material Changes vs. Prior Period
- Strategic Pivot: The Company shifted from a manufacturing model to a digital asset treasury model in August 2025. This resulted in the recognition of $2.21 million in staking revenue and a $15.50 million unrealized gain on digital assets for the quarter.
- Revenue Composition: Product revenue remains negligible ($83,622 for Q3) compared to the new staking revenue stream. The Company recorded a gross loss on product sales due to inventory reserves ($924,010) established to terminate manufacturing.
- Explosive Expense Growth: Selling, General, and Administrative (SG&A) expenses surged to $110.72 million in Q3 2025 from $1.87 million in Q3 2024. This increase is primarily driven by a $101.33 million non-cash stock-based compensation charge related to warrants issued to a strategic advisor.
- Asset Impairment: The Company recorded a $7.50 million impairment of long-lived fixed assets associated with the pending sale of its Hungarian subsidiary (Safegard Medical Kft).
- Liquidity Transformation: Total assets increased from $7.31 million (Dec 2024) to $443.96 million (Sep 2025), driven by a $411 million capital raise in August 2025 (cash, stablecoins, and SOL).
Guidance, Outlook, and Risks
- Capital Raise: In August 2025, the Company completed a $411 million offering (Cash and Cryptocurrency Securities Purchase Agreements), receiving net proceeds of $403 million. This included cash, USDC, and SOL tokens.
- Share Repurchase: In October 2025 (Subsequent Event), the Board approved a $100 million share repurchase program.
- Settlement of Litigation: In October 2025, the Company settled outstanding litigation with Barry Berler and Plastomold Industries. As part of the settlement, the Company transferred its Hungarian subsidiary and related assets to the counterparties.
- Key Risks:
- Digital Asset Volatility: The Company holds ~$404 million in SOL. A 10% fluctuation in SOL price would impact pre-tax income by approximately $40.4 million.
- Concentration Risk: The treasury strategy is heavily concentrated in a single digital asset (SOL).
- Related Party Transactions: Significant consulting fees ($10.7 million annual commitment) and warrant issuances were made to entities controlled by the brother of the Chief Investment Officer.
Investor Verification Checklist
- Valuation of Digital Assets: Verify the fair value methodology for locked vs. liquid SOL and the 10% discount applied to locked tokens.
- Stock-Based Compensation: Review the $101.33 million warrant issuance to the Strategic Advisor (Sol Markets) and the related party nature of this transaction.
- Manufacturing Exit: Confirm the status of the Hungarian subsidiary spin-off and the finality of the manufacturing termination.
- Derivative Exposure: Assess the $7.63 million margin loan and derivative liabilities ($446,876) used to manage SOL exposure.
- Going Concern: Note that management asserts the new liquidity position removes substantial doubt regarding the Company's ability to continue as a going concern.